Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results

Coya Therapeutics (NASDAQ:COYA) announced its earnings results on Wednesday. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.12), Zacks reports.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA traded down $0.17 during mid-day trading on Wednesday, hitting $5.84. The company’s stock had a trading volume of 57,014 shares, compared to its average volume of 100,236. Coya Therapeutics has a one year low of $4.65 and a one year high of $8.29. The company’s fifty day simple moving average is $6.11 and its 200-day simple moving average is $6.05. The stock has a market cap of $97.73 million, a price-to-earnings ratio of -4.73 and a beta of 0.20.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on COYA shares. Lake Street Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, November 5th. BTIG Research reissued a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Tuesday, September 30th. D. Boral Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, September 29th. Chardan Capital reiterated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday, September 17th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, August 25th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. bought a new stake in shares of Coya Therapeutics during the third quarter worth $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Coya Therapeutics during the 2nd quarter worth about $119,000. Finally, Jane Street Group LLC lifted its position in shares of Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after buying an additional 13,176 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.